<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01307332</url>
  </required_header>
  <id_info>
    <org_study_id>H10-02482</org_study_id>
    <secondary_id>142402</secondary_id>
    <nct_id>NCT01307332</nct_id>
  </id_info>
  <brief_title>Advanced MRI Measures of Repair in Alemtuzumab Treated Patients</brief_title>
  <acronym>iCAMMS-IST</acronym>
  <official_title>Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are two parts to this investigator sponsored trial (IST):&#xD;
&#xD;
        1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.&#xD;
&#xD;
        2. To provide serum samples for the University of Southern California (USC) ICAM125&#xD;
           lymphocyte recovery study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous&#xD;
      System (CNS). There are many forms of MS; although the majority are Relapsing Remitting&#xD;
      (RRMS) representing approximately 80% of the cases. The disease appears to be more&#xD;
      inflammatory in RRMS as manifested by an increase in Gadolinium (Gd) enhancement on MRI and&#xD;
      an increase in inflammatory bio-assay markers.&#xD;
&#xD;
      Alemtuzumab; a humanized monoclonal antibody that targets the CD52 molecule present on T and&#xD;
      B lymphocytes, natural killer (NK) cells, and monocytes and macrophages; effects rapid and&#xD;
      sustained lymphocyte depletion and is approved for the treatment of B-cell chronic&#xD;
      lymphocytic leukemia in many countries under the names CAMPATH or MabCAMPATH.&#xD;
&#xD;
      There are two parts to this Investigator Sponsored Trial (IST):&#xD;
&#xD;
        1. To perform advanced serial MRI studies on patients initiating alemtuzumab therapy.&#xD;
&#xD;
        2. To provide serum samples for the University of Southern California (USC) ICAM125&#xD;
           lymphocyte recovery study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in normal appearing white matter from baseline through month 24.</measure>
    <time_frame>24 months</time_frame>
    <description>The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify specific changes in T cell subsets and functions in Relapsing Remitting Multiple Sclerosis from baseline through month 48.</measure>
    <time_frame>48 months</time_frame>
    <description>Analyzing changes is immune responsiveness may reveal critical information about the mechanisms by which alemtuzumab acts, confirm the importance of specific immune cell types or molecules as targets for alemtuzumab treatment or may also be useful for monitoring drug effectiveness and safety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>MabCampath-1h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm, single cohort study, all subjects will be dosed with alemtuzumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MabCampath-1h</intervention_name>
    <description>Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.</description>
    <arm_group_label>MabCampath-1h</arm_group_label>
    <other_name>Alemtuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed, informed consent form&#xD;
&#xD;
          -  Age 18 to 50 years old (inclusive)&#xD;
&#xD;
          -  Diagnosis of MS per update of McDonald criteria, and cranial MRI scan demonstrating&#xD;
             white matter lesions attributable to MS within 10 years of screening&#xD;
&#xD;
          -  Onset of MS symptoms within 15 years of screening&#xD;
&#xD;
          -  Neurostatus (EDSS) score 0.0 to 5.0 (inclusive)&#xD;
&#xD;
          -  2 MS attacks (first episode or relapse) occurring in the 24 months prior to screening,&#xD;
             with 1 attack in the 12 months prior to screening, with objective neurological signs&#xD;
             confirmed by a physician.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received prior therapy for MS other than corticosteroids within 28 days of screening;&#xD;
             e.g., interferon's, IV immunoglobulin, and glatiramer acetate&#xD;
&#xD;
          -  Exposure to natalizumab within 6 months of screening&#xD;
&#xD;
          -  Any prior exposure to mitoxantrone, mycophenolate mofetil, azathioprine, cladribine,&#xD;
             cyclophosphamide, cyclosporine A, methotrexate, rituximab, or any other&#xD;
             immunosuppressive agent other than systemic corticosteroid treatment&#xD;
&#xD;
          -  Has any progressive form of MS&#xD;
&#xD;
          -  History of malignancy (exception for basal cell skin carcinoma)&#xD;
&#xD;
          -  Previous hypersensitivity reaction to other immunoglobulin product&#xD;
&#xD;
          -  Intolerance of pulsed corticosteroids, especially a history of steroid psychosis&#xD;
&#xD;
          -  CD4+, CD8+, or CD19+ (i.e., absolute CD3+CD4+, CD3+CD8+, or CD19+/mm3) count &lt;LLN at&#xD;
             Screening; if abnormal cell count(s) return to within normal limits, eligibility may&#xD;
             be reassessed&#xD;
&#xD;
          -  Seropositivity for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Significant autoimmune disease (e.g, immune cytopenias, rheumatoid arthritis, systemic&#xD;
             lupus erythematosus, other connective tissue disorders; vasculitis; inflammatory bowel&#xD;
             disease; severe psoriasis)&#xD;
&#xD;
          -  Presence of anti-thyroid stimulating hormone (TSH) receptor (TSHR) antibodies&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Latent tuberculosis unless effective anti-tuberculosis therapy has been completed, or&#xD;
             active tuberculosis.&#xD;
&#xD;
          -  Infection with hepatitis B virus or hepatitis C virus&#xD;
&#xD;
          -  Of childbearing potential with a positive serum pregnancy test&#xD;
&#xD;
          -  Unwilling to agree to use a reliable and acceptable contraceptive method throughout&#xD;
             the study period&#xD;
&#xD;
          -  Major psychiatric disorder that is not adequately controlled by treatment&#xD;
&#xD;
          -  Epileptic seizures that are not adequately controlled by treatment&#xD;
&#xD;
          -  Major systemic disease or other illness that would, in the opinion of the&#xD;
             Investigator, compromise patient safety or interfere with the interpretation of study&#xD;
             results&#xD;
&#xD;
          -  Medical, psychiatric, cognitive, or other conditions&#xD;
&#xD;
          -  Confirmed platelet count the lower limit of normal (LLN) of the evaluating laboratory&#xD;
             at Screening or documented at 100,000/L within the past year on a sample without&#xD;
             clumping&#xD;
&#xD;
          -  Prior history of invasive fungal infections&#xD;
&#xD;
          -  Cervical high risk human papilloma virus (HPV) positivity or abnormal cervical&#xD;
             cytology other than abnormal squamous cells of undetermined significance (ASCUS).&#xD;
&#xD;
          -  Seropositive for Trypanosoma cruzi or the Human T-lymphotropic virus type I or type II&#xD;
             (HTLV-I/II) (testing required in endemic regions only)&#xD;
&#xD;
          -  Any other illness or infection (latent or active) that, in the Investigator's opinion,&#xD;
             could be exacerbated by alemtuzumab treatment&#xD;
&#xD;
          -  Any hepatic or renal function value grade 2 or higher at Screening, with the exception&#xD;
             of hyperbilirubinemia due to Gilbert's syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Traboulsee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.</citation>
    <PMID>18946064</PMID>
  </reference>
  <reference>
    <citation>Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.</citation>
    <PMID>16044212</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2011</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Anthony Traboulsee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>RRMS</keyword>
  <keyword>Alemtuzumab</keyword>
  <keyword>Demyelination</keyword>
  <keyword>Remyelination</keyword>
  <keyword>Tolerogenic</keyword>
  <keyword>T cells</keyword>
  <keyword>Demyelinating Autoimmune Diseases, CNS</keyword>
  <keyword>Autoimmune Diseases of the Nervous System</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Demyelinating Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

